Hepatitis C virus (HCV) envelope glycoproteins E1 and E2 are responsible for cell entry,
with E2 being the major target of neutralizing antibodies (NAbs). Here, we present a …

… Author contributions: Fang Chen, Kenna Nagy, and Mansun Law designed and conceived
the study. Kenna Nagy and Andrew Honda coordinated mouse immunization, assessed …

To achieve global elimination of hepatitis C virus (HCV), an effective cross-genotype vaccine
is needed. The HCV envelope glycoprotein E2 is the main target for neutralizing antibodies …

Human IGHV1-69-encoded broadly neutralizing antibodies (bnAbs) that target the hepatitis
C virus (HCV) envelope glycoprotein (Env) E2 are important for protection against HCV …

Elicitation of broadly neutralizing antibodies (bnAbs) is a leading strategy in rational vaccine
design against antigenically diverse pathogens. Here, we studied a panel of monoclonal …

Type 1 diabetes (T1D) is a prototypic T cell–mediated autoimmune disease. Because the
islets of Langerhans are insulated from blood vessels by a double basement membrane and …

Understanding antibody specificity and defining response profiles to antigens continue to
be essential to both vaccine research and therapeutic antibody development. Peptide …

Antibiotic resistance threatens clinical control of bacterial infections while the genetic
adaptability of microbes continues to outpace small-molecule development. The combinatorial …

Hepatitis C virus (HCV) envelope glycoproteins E1 and E2 are critical for cell entry with E2
being the major target of neutralizing antibodies (NAbs). Here, we present a comprehensive …

The increasing frequency and intensity of wildfires in Southwestern ponderosa pine and
mixed-conifer forests pose significant threats to biodiversity and ecosystem resilience. In …